Astec LifeSciences Limited (Astec) announced its financial results for the fourth Quarter & Year ended March 31, 2025.

Astec Lifesciences has reported net loss of Rs 16.09 crore in the quarter ended March 2025 as against net loss of Rs 0.97 crore during the quarter ended March 2024. Sales declined 22.26 per cent to Rs. 119.53 crore in the quarter ended March 2025 as against Rs. 153.75 crore during the quarter ended March 2024.

For the Financial Year ended March 31, 2025, Astec reported net loss of Rs 134.75 crore as against net loss of Rs 46.93 crore during the previous year ended March 2024. Sales declined 16.78 per cent to Rs 381.30 crore in the year ended March 2025 as against Rs 458.18 crore during the previous year ended March 2024.

Commenting on the performance, N. B. Godrej, Chairman, Astec LifeSciences Limited, said: “In Q4 FY25 Astec reported sequential improvement in performance. EBITDA for Q4 FY25 at Rs. 6.8 crore showed an improvement over the earlier quarters. This positive trend was primarily due to increase in volumes and prices in Enterprise business coupled with improved product mix in the CDMO business.

“We expect uptick in the demand for Enterprise & CDMO businesses and a gradual improvement in the performance in the coming year.”